Last reviewed · How we verify
Placebo "30, 50 or 70 mg"
Placebo produces therapeutic effects through the patient's expectation and belief in treatment, activating endogenous neurobiological pathways independent of pharmacological action.
Placebo produces therapeutic effects through the patient's expectation and belief in treatment, activating endogenous neurobiological pathways independent of pharmacological action. Used for Research and clinical trial control comparator.
At a glance
| Generic name | Placebo "30, 50 or 70 mg" |
|---|---|
| Also known as | Sugar pill |
| Sponsor | Rochester Center for Behavioral Medicine |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Behavioral Medicine |
| Phase | FDA-approved |
Mechanism of action
Placebo effects are mediated by psychological expectation and conditioning, which can activate endogenous neurotransmitter systems, reduce pain perception, and modulate immune and autonomic nervous system responses. The effect is particularly pronounced in conditions with subjective symptomatology such as pain, nausea, and anxiety. While placebo contains no active pharmaceutical ingredient, the ritual of treatment and patient belief can produce measurable clinical improvements in certain conditions.
Approved indications
- Research and clinical trial control comparator
Common side effects
- Nocebo effects (adverse events attributed to placebo)
Key clinical trials
- Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome (PHASE4)
- A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD) (PHASE3)
- Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE4)
- Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) (PHASE3)
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder (PHASE3)
- Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder (PHASE3)
- A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD (PHASE3)
- Effect of Vyvanse on Driving in Young Adults With ADHD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo "30, 50 or 70 mg" CI brief — competitive landscape report
- Placebo "30, 50 or 70 mg" updates RSS · CI watch RSS
- Rochester Center for Behavioral Medicine portfolio CI